benzbromarone has been researched along with Disease Exacerbation in 6 studies
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Considering the increased prevalence of diabetes mellitus (DM) in the gout population, this study evaluated the effects of benzbromarone, a uricosuric agent, on the incidence of DM in the gout population." | 7.88 | Decreased incidence of diabetes in patients with gout using benzbromarone. ( Chang, KT; Chang, YH; Chiu, YW; Hung, CC; Hwang, SJ; Kuo, IC; Lin, HY; Lin, SF; Niu, SW; Ta, A, 2018) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 5.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| " Considering the increased prevalence of diabetes mellitus (DM) in the gout population, this study evaluated the effects of benzbromarone, a uricosuric agent, on the incidence of DM in the gout population." | 3.88 | Decreased incidence of diabetes in patients with gout using benzbromarone. ( Chang, KT; Chang, YH; Chiu, YW; Hung, CC; Hwang, SJ; Kuo, IC; Lin, HY; Lin, SF; Niu, SW; Ta, A, 2018) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 1.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, TT | 1 |
| Yu, KH | 1 |
| Kuo, CF | 1 |
| Luo, SF | 1 |
| Chiou, MJ | 1 |
| Lan, WC | 1 |
| Chen, JS | 1 |
| Tseng, WY | 1 |
| Hsieh, AH | 1 |
| Wang, LC | 1 |
| Chou, HW | 1 |
| Chiu, HT | 1 |
| Tsai, CW | 1 |
| Ting, IW | 1 |
| Yeh, HC | 1 |
| Huang, HC | 1 |
| Kuo, CC | 1 |
| Niu, SW | 1 |
| Chang, KT | 1 |
| Ta, A | 1 |
| Chang, YH | 1 |
| Kuo, IC | 1 |
| Hung, CC | 1 |
| Chiu, YW | 1 |
| Hwang, SJ | 1 |
| Lin, SF | 1 |
| Lin, HY | 1 |
| Stamp, LK | 1 |
| Haring, B | 1 |
| Kudlich, T | 1 |
| Rauthe, S | 1 |
| Melcher, R | 1 |
| Geier, A | 1 |
| Lhotta, K | 1 |
1 review available for benzbromarone and Disease Exacerbation
| Article | Year |
|---|---|
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
5 other studies available for benzbromarone and Disease Exacerbation
| Article | Year |
|---|---|
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gou | 2019 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; | 2018 |
Decreased incidence of diabetes in patients with gout using benzbromarone.
Topics: Adult; Benzbromarone; Comorbidity; Diabetes Mellitus; Disease Progression; Dose-Response Relationshi | 2018 |
Benzbromarone: a double-edged sword that cuts the liver?
Topics: Aged; Benzbromarone; Biopsy; Chemical and Drug Induced Liver Injury; Disease Progression; Fatal Outc | 2013 |
Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
Topics: Benzbromarone; Disease Progression; Humans; Hyperuricemia; Kidney Diseases; Uricosuric Agents | 2003 |